Financial Performance - Total revenue for the year ended December 31, 2024, was approximately RMB 5,258.9 million, a decrease of 3.2% from RMB 5,431.0 million in 2023[3] - Gross profit for the year was approximately RMB 1,739.3 million, with a gross margin of 33.1%, compared to a gross profit of RMB 940.9 million and a margin of 17.3% in 2023[3] - Profit attributable to equity holders of the parent company was approximately RMB 646.7 million, a significant recovery from a loss of RMB 783.3 million in 2023[3] - The net profit turned positive, amounting to approximately RMB 624.9 million, with profit attributable to equity holders of the company at approximately RMB 646.7 million[10] - The pre-tax profit for the group was RMB 640,893,000 in 2024, down from RMB 744,375,000 in 2023, indicating a decline of about 14%[68] - The total income tax expense for the year was RMB 101,311,000 in 2024, compared to a tax credit of RMB 126,175,000 in 2023[71] - Basic and diluted earnings per share were RMB 0.44, compared to a loss per share of RMB 0.53 in 2023[34] Revenue Breakdown - The sales revenue from the formulation business was approximately RMB 2,986.1 million, with a gross margin of 31.8%, compared to RMB 2,979.0 million and a margin of 43.1% in 2023[3] - The API business generated sales revenue of approximately RMB 1,065.7 million, with a gross margin of 38.6%, compared to RMB 1,307.3 million and a margin of -42.8% in 2023[3] - The CDMO business reported sales revenue of approximately RMB 1,033.8 million, with a gross margin of 32.9%, up from RMB 967.0 million and a margin of 22.0% in 2023[3] - The Heparin value chain business generated sales revenue of approximately RMB 4,051.8 million, a year-on-year decrease of about 5.5%[12] - The group's API business sales revenue was approximately RMB 1,065.7 million, a year-on-year decrease of about 18.5%, while sales volume increased by approximately 10.8% compared to the same period in 2023, with a gross margin of approximately 38.6%[15] - CDMO services revenue increased by 6.9% to approximately RMB 1,033.8 million, contributing 19.7% to total revenue[26] Asset and Liability Management - Non-current assets totaled RMB 7,722.3 million, a decrease from RMB 8,599.1 million in 2023[6] - Current assets decreased to RMB 9,621.3 million from RMB 10,604.3 million in 2023, primarily due to a reduction in inventory[6] - Current liabilities decreased to RMB 3,699.2 million from RMB 4,986.2 million in 2023, reflecting improved liquidity management[6] - Total assets as of December 31, 2024, were approximately RMB 17,343.5 million, compared to RMB 19,203.4 million in 2023, with a debt-to-asset ratio of about 29.6%[40] - The total liabilities for the year ended December 31, 2024, were RMB 5,141,403,000, down from RMB 7,215,040,000 in 2023, reflecting a reduction of approximately 28.73%[54][56] Cash Flow and Financing - The company's cash flow from operating activities increased by approximately 451.0% to about RMB 2,194.1 million, compared to approximately RMB 398.2 million in 2023[9] - Financing costs decreased by approximately RMB 82.9 million to about RMB 145.2 million, a reduction of about 36.3% compared to RMB 228.1 million in 2023[30] - Cash and bank balances as of December 31, 2024, were approximately RMB 1,421.8 million, down from RMB 1,765.6 million in 2023[36] - Interest-bearing bank and other borrowings amounted to approximately RMB 3,448.2 million as of December 31, 2024, down from RMB 5,434.6 million in 2023[42] Dividends and Shareholder Information - The board proposed a final cash dividend of RMB 2.5 per share, with a payout ratio of 56.7%, compared to no dividend in 2023[3] - Proposed final dividend for 2024 is RMB 0.25 per share, totaling RMB 366,824 thousand, compared to no dividend in 2023[75] - The annual general meeting for the year 2024 will be held on May 22, 2025, with a notice to be published in due course[86] Research and Development - The group incurred research and development costs of RMB 212,036,000 in 2024, an increase of 16% from RMB 182,433,000 in 2023[68] - The candidate drug H1710 received approval for clinical trials from the National Medical Products Administration, indicating progress in the development of a new cancer treatment[18] - Oregovomab, a candidate drug for advanced ovarian cancer, is undergoing patient survival follow-up after a mid-term analysis of its Phase III clinical trial did not meet expected goals[19] - AR-301, a monoclonal antibody targeting Staphylococcus aureus, has received Fast Track designation from the FDA and orphan drug status from the EMA, with plans for a second Phase III study based on promising data in specific patient groups[20] Market Strategy and Operations - The company is focusing on enhancing its business capabilities and operational quality while optimizing its business structure to improve sales growth and operating profit[9] - The company plans to continue its globalization strategy, deepening its market presence in Europe, China, the United States, and other non-European and American markets[9] - The group is actively adjusting market strategies to cope with competitive pressures, focusing on maintaining price systems and enhancing product competitiveness[15] - The group is expanding its market coverage and deepening existing customer relationships while actively developing new customer bases in the CDMO sector[16] Compliance and Governance - The audit committee reviewed the consolidated annual performance for the year ending December 31, 2024, and confirmed compliance with relevant accounting standards and regulations[90] - Ernst & Young confirmed that the financial figures in the preliminary announcement align with the consolidated financial statements for the year ending December 31, 2024[91] - The company has not made any significant acquisitions or disposals of subsidiaries, associates, or joint ventures during the reporting period[81]

深圳市海普瑞药业集团股份有限公司全体股东 : 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计 了深圳市海普瑞药业集团股份有限公司 2024 年 12 月 31 日的财务报告内部控制的有效 性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指 引》的规定,建立健全和有效实施内部控制,并评价其有效性是深圳市海普瑞药业集团 股份有限公司董事会的责任。 二、注册会计师的责任 Ernst & Young Hua Ming I I P Level 17 Frnst & Young Tower Oriental Plaza. 1 East Chang An Avenue Donachena District Beiling, China 100738 安永华明会计师事务所(特殊普通合伙 中国北京市东城区东长安街1号 东方广场安永大楼 17 层 邮政编码:100738 传直 : +86 10 8518 8298 内部控制审计报告 安永华明(2025) 专字第70015147 H01号 深圳市海普瑞药业集团股份有限公司 内部控制审计报告(续) 我 ...

安永华明(2025) 专字第70015147 H02号 深圳市海普瑞药业集团股份有限公司 深圳市海普瑞药业集团股份有限公司董事会: 我们审计了深圳市海普瑞药业集团股份有限公司的2024年度财务报表,包括2024 年12月31日的合并及公司资产负债表,2024年度的合并及公司利润表、股东权益变动 表和现金流量表以及相关财务报表附注,并于2025年3月28日出具了编号为安永华明 (2025) 审字第70015147 H01号的无保留意见审计报告。 按照《上市公司监管指引第8号 -- 上市公司资金往来、对外担保的监管要求》的 要求,深圳市海普瑞药业集团股份有限公司编制了后附的2024年度非经营性资金占用 及其他关联资金往来情况汇总表(以下简称"汇总表"）。 如实编制和对外披露汇总表,并确保其真实性、合法性、完整性是深圳市海普瑞 药业集团股份有限公司的责任。我们对汇总表所载资料与我们审计深圳市海普瑞药业 集团股份有限公司2024年度财务报表时所复核的会计资料和经审计的财务报表的相关 内容进行了核对,在所有重大方面没有发现不一致之处。除了对深圳市海普瑞药业集 团股份有限公司2024年度财务报表出具审计报告而执行的审计程 ...

深圳市海普瑞药业集团股份有限公司 已审财务报表 2024年度 深圳市海普瑞药业集团股份有限公司 目 录 | | 页 | | 次 | | --- | --- | --- | --- | | 审计报告 | 1 | - | 8 | | 已审财务报表 | | | | | 合并资产负债表 | 9 | - | 11 | | 合并利润表 | 12 | - | 13 | | 合并股东权益变动表 | 14 | - | 15 | | 合并现金流量表 | 16 | - | 17 | | 公司资产负债表 | 18 | - | 19 | | 公司利润表 | | 20 | | | 公司股东权益变动表 | 21 | - | 22 | | 公司现金流量表 | 23 | - | 24 | | 财务报表附注 | 25 | - | 164 | | 补充资料 | | | | | 1.非经常性损益明细表 | | 165 | | | 2.净资产收益率和每股收益 | | 166 | | | 3.中国企业会计准则与国际财务报告准则编报差异调节表 | | 166 | | 审计报告 安永华明（2025）审字第70015147_H01号 深圳市海普瑞药业集团股份 ...

深圳市海普瑞药业集团股份有限公司 独立董事 2024 年度述职报告 各位股东及代表： 本人作为深圳市海普瑞药业集团股份有限公司（以下简称"公司"）的独立 董事，按照《公司法》《上市公司独立董事管理办法》《独立董事工作制度》《公 司章程》及有关法律、法规的规定，出席相关会议，审议会议各项议案，并对董 事会的相关议案发表意见，恪尽职守、勤勉尽责地履行了独立董事职责。现将 2024 年的工作情况简要汇报如下： 一、 独立董事的基本情况 本人吕川，中国国籍（香港），华中科技大学管理学博士。曾任南京金陵船 厂有限公司助理工程师、深圳市有色金属财务有限公司投资银行部研究员、银建 国际实业有限公司总经理助理及副总经理、深圳中青宝互动网络股份有限公司董 事、中国地热能产业发展集团有限公司非执行董事、易大宗控股有限公司非执行 董事、宁夏昊王酒业有限公司董事。2019 年 10 月起担任兴业合金材料集团有限 公司副总裁。现任公司独立董事。 作为公司的独立董事，本人符合《上市公司独立董事管理办法》《深圳证券 交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关法律法 规中对独立董事独立性的相关要求，不存在影响独立性 ...

独立董事 2024 年度述职报告 各位股东及代表： 本人作为深圳市海普瑞药业集团股份有限公司（以下简称"公司"）的独立 董事，按照《公司法》《上市公司独立董事管理办法》《独立董事工作制度》《公 司章程》及有关法律、法规的规定，出席相关会议，审议会议各项议案，并对董 事会的相关议案发表意见，恪尽职守、勤勉尽责地履行了独立董事职责。现将 2024 年的工作情况简要汇报如下： 一、 独立董事的基本情况 深圳市海普瑞药业集团股份有限公司 作为公司的独立董事，本人符合《上市公司独立董事管理办法》《深圳证券 交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关法律法 规中对独立董事独立性的相关要求，不存在影响独立性的情况。 二、 独立董事 2024 年度履职情况 （一）2024 年度出席董事会和股东大会的情况 报告期内，公司共召开 2 次股东大会，6 次董事会，出席详细情况见下表： | 本报告期应 | 现场出席董 | 以通讯方式 | 委托出席董 | 是否连续两 缺席董事会 | 次未亲自参 | 出席股东大 | | --- | --- | --- | --- | --- | --- | --- | | 参加董 ...

深圳市海普瑞药业集团股份有限公司 独立董事 2024 年度述职报告 各位股东及代表： 本人作为深圳市海普瑞药业集团股份有限公司（以下简称"公司"）的独立 董事，按照《公司法》《上市公司独立董事管理办法》《独立董事工作制度》《公 司章程》及有关法律、法规的规定，出席相关会议，审议会议各项议案，并对董 事会的相关议案发表意见，恪尽职守、勤勉尽责地履行了独立董事职责。现将 2024 年的工作情况简要汇报如下： 一、 独立董事的基本情况 本人易铭，中国国籍（香港），英国雷丁大学金融学硕士，北京大学 EMBA 硕士。曾任中国信达（香港）资产管理公司投行部高级经理、投资部总经理，行 健（亚洲）资产管理公司管理合伙人。现任亚太航空租赁集团有限公司首席财务 官、公司独立董事。 作为公司的独立董事，本人符合《上市公司独立董事管理办法》《深圳证券 交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关法律法 规中对独立董事独立性的相关要求，不存在影响独立性的情况。 二、 独立董事 2024 年度履职情况 （一）2024 年度出席董事会和股东大会的情况 报告期内，公司共召开 2 次股东大会，6 次董事会，出席详细情况 ...

Financial Performance - The company's operating revenue for 2024 was ¥5,280,713,410.80, a decrease of 3.03% compared to ¥5,445,572,060.12 in 2023[6]. - The net profit attributable to shareholders for 2024 was ¥646,741,666.49, representing a significant increase of 182.57% from a loss of ¥783,258,039.42 in 2023[6]. - The cash flow from operating activities reached ¥2,194,132,237.51, marking a substantial increase of 450.99% compared to ¥398,215,676.99 in 2023[6]. - Basic earnings per share for 2024 were ¥0.4408, a turnaround from a loss of ¥0.5338 in 2023, reflecting an increase of 182.58%[6]. - The total assets at the end of 2024 were ¥17,343,523,964.97, a decrease of 9.69% from ¥19,203,415,131.24 at the end of 2023[6]. - The company reported a weighted average return on equity of 5.39% for 2024, an improvement of 11.99% from -6.60% in 2023[6]. - The company experienced a significant increase in net profit excluding non-recurring gains and losses, which was ¥253,544,139.42 in 2024 compared to a loss of ¥779,841,459.91 in 2023, an increase of 132.51%[6]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 2.50 per 10 shares to all shareholders, based on a total of 1,467,296,204 shares[5]. - The cash dividend plan for 2024 proposes a distribution of ¥366,824,051, with a per-share dividend of ¥2.50 based on a total share capital of 1,467,296,204 shares[157]. - The company will not distribute cash dividends or issue bonus shares for the 2023 fiscal year, as approved in the shareholder meeting[155]. Business Operations - The company has not reported any changes in its main business operations since its listing[20]. - The company operates under the supervision of the National Medical Products Administration and adheres to Good Manufacturing Practices (GMP)[15]. - The company's main business includes the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization[34]. - The heparin product line includes enoxaparin sodium preparations and heparin sodium raw materials, with a focus on high-quality and effective medications[35]. - The company has developed approximately 200 different molecular structures in the CDMO sector, demonstrating strong delivery records[38]. - The company provides comprehensive CDMO services, including development and cGMP manufacturing for biopharmaceuticals[43]. Market and Economic Environment - The company faced challenges in the global economy, with the IMF projecting global growth rates of 3.2% and 3.3% for 2024 and 2025 respectively[31]. - The company noted that the European economy is under pressure due to energy price fluctuations and geopolitical risks, impacting overall growth[31]. - The Asian market showed mixed performance, with China maintaining growth resilience despite internal demand weakening, while India is expected to exceed a growth rate of 6%[31]. - The company has seen a 5% year-on-year growth in GDP, indicating a positive economic environment for its operations[33]. Research and Development - R&D expenses increased by 16.23% to CNY 212,035,640.41, primarily due to increased investment in research projects[77]. - The company aims to enhance product quality through advanced research projects, including the synthesis of heparin precursors and polysaccharides[79]. - The company plans to accelerate the drug development process for RVX-208, which has received breakthrough therapy designation from the FDA[65]. - The company is committed to optimizing organizational structure and resource allocation to improve operational efficiency and profitability[111]. Risk Management - The company has detailed its future risks and corresponding mitigation strategies in the report[5]. - The company faces risks associated with new drug development, including potential failures during clinical trials, and will continue to manage resources effectively to advance its pipeline[117]. - The company faces significant foreign exchange risk due to major revenues coming from overseas markets, primarily settled in euros and US dollars, which may lead to substantial exchange gains or losses[118]. - The company has established a financial derivatives trading management system to mitigate risks associated with derivative transactions[100]. Corporate Governance - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[125]. - The company maintains a transparent information disclosure system, ensuring all investors have equal access to information[127]. - The company has implemented a strict insider information management system, with no reported insider trading incidents during the reporting period[128]. - The company actively engages with investors to enhance understanding and communication, adhering to investor relations management regulations[127]. Environmental Compliance - The company strictly adhered to multiple environmental protection laws and standards during its operations, including the Air Pollution Prevention and Control Law[169]. - The company holds valid pollution discharge permits for its facilities, with the latest permit for the Pingshan plant valid until October 29, 2029[170]. - The company reported a total emission of VOCs at 2.979 tons per year, which is within the regulatory limits[171]. - The company has established comprehensive wastewater and waste gas treatment facilities, ensuring that wastewater discharge is below the total amount approved by the discharge permit[175]. Employee and Management Structure - The total number of employees at the end of the reporting period is 1,926, with 839 in the parent company and 1,087 in major subsidiaries[150]. - The professional composition includes 680 production personnel, 123 sales personnel, 787 technical personnel, 64 financial personnel, and 272 administrative personnel[150]. - The company emphasizes a competitive and fair compensation policy, aligning employee remuneration with performance and market standards[152]. - The company has a performance evaluation system for determining the remuneration of directors and senior management[141].

证券代码：002399 证券简称：海普瑞 公告编号：2025-010 深圳市海普瑞药业集团股份有限公司 关于公司2024年计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《企业会计准则第 22 号—金融工具确认和计量》的规定，公司以预期 信用损失为基础，对以摊余成本计量的金融资产、以公允价值计量且其变动计入 其他综合收益的债务工具投资、租赁应收款、合同资产进行减值处理并确认损失 准备。 对于不含重大融资成分的应收款项以及合同资产，公司运用简化计量方法， 按照相当于整个存续期内的预期信用损失金额计量损失准备。 对于租赁应收款，包含重大融资成分的应收款项以及合同资产，公司选择运 用简化计量方法，按照相当于整个存续期内的预期信用损失金额计量损失准备。 深圳市海普瑞药业集团股份有限公司（以下简称"公司"）根据《深圳证券 交易所上市公司自律监管指南第 1 号——业务办理》《企业会计准则》及公司相 关会计政策的规定，在编制 2024 年度公司财务报表的过程中，为了真实、准确 的反映公司的资产与财务状况，对合并报表范围内的 2024 年度各类应收 ...

安永华明会计师事务所（特殊普通合伙）（以下简称"安永华明"）于 1992 年 9 月成立，注册地址为北京市东城区东长安街 1 号东方广场安永大楼 17 层 01-12 室。截至 2024 年末，拥有合伙人 251 人，首席合伙人为毛鞍宁先生，拥有执业 注册会计师逾 1700 人，其中拥有证券相关业务服务经验的执业注册会计师超过 1,500 人，注册会计师中签署过证券服务业务审计报告的注册会计师逾 500 人。 深圳市海普瑞药业集团股份有限公司 董事会审计委员会对会计师事务所 2024 年度 履行监督职责情况报告 根据《上市公司治理准则》《国有企业、上市公司选聘会计师事务所管理办 法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 《公司章程》及《董事会专门委员会工作细则》等规定和要求，深圳市海普瑞药 业集团股份有限公司（以下简称"公司"）董事会审计委员会本着勤勉尽责的原 则，恪尽职守，审慎履行对会计师事务所的监督职责，具体情况如下： 一、境内会计师事务所基本情况 （二）2024 年 4 月 29 日，公司召开第六届董事会审计委员会第五次会议， 审议通过了《关于续聘会计师事务所的议案》 ...